Medicinova Inc (MNOV)

$1.60 +0.02 (1.27%)
Market Cap 77.65M
Revenue (ttm) 0.00
Net Income (ttm) -11.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 71,800
Avg Vol 119,902
Day's Range N/A - N/A
Shares Out 49.15M
Stochastic %K 85%
Beta 0.52
Analysts Strong Sell
Price Target $8.33

Company Profile

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical my...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 373 1500
Fax: 858 404 0048
Address:
4275 Executive Square, Suite 300, La Jolla, United States
MuzunguZanz
MuzunguZanz Jan. 15 at 8:41 PM
$MNOV This is a 8-10 months investment but if successful you guys should be at $10
1 · Reply
thepalace2007
thepalace2007 Jan. 9 at 5:44 PM
$MNOV $5 incoming
1 · Reply
Penhouseview
Penhouseview Jan. 8 at 3:10 AM
$MNOV
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 2 at 1:37 AM
$MNOV RSI: 20.59, MACD: -0.0432 Vol: 0.11, MA20: 1.44, MA50: 1.42 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
StockElementCorporation
StockElementCorporation Dec. 30 at 1:56 PM
Premarket movers 📈 Upside: $EKSO +44% (APLD to spin out cloud business; proposes combination with Ekso to launch Chronoscale) $ONTF +36% (to be acquired by Cvent for $8.10/share, ~$400M) $SCWO +13% (awarded PFAS waste destruction project for City of St. Cloud) $MNOV +5.5% (announces up to $50M equity distribution agreement) $TE +5.0% (executes $160M sale of Section 45X tax credits) DUOT +3.2% (announces additional Texas deployment and Illinois expansion) MOH +2.7% (constructive comments from Mike Burry) APLD +2.1% (cloud business spinout, Ekso combination proposal) Downside: IFRX -4.9% (Vilobelimab Phase 3 post-hoc analyses in pyoderma gangrenosum)
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 26 at 3:52 PM
$MNOV Share Price: $1.24 Contract Selected: Jul 17, 2026 $2.5 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.07 – $0.09 Potential Upside: 59% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
LimeLightL
LimeLightL Dec. 25 at 9:37 AM
$MNOV Expectations reset as evidence replaces narrative, given the heightened sensitivity to timeline slippage. Shortfalls would likely reprice expectations quickly.
1 · Reply
prismmarketview
prismmarketview Dec. 18 at 4:11 PM
MediciNova (NASDAQ: $MNOV ) has completed enrollment in its investigator‑initiated Phase 2 OXTOX trial evaluating MN‑166 (ibudilast) to prevent chemotherapy‑induced peripheral neuropathy in metastatic colorectal cancer, with 100 patients randomized across 11 Australian sites and top‑line data expected in late 2026 after six‑month post‑chemo follow‑up. https://prismmarketview.com/medicinova-completes-enrollment-in-phase-2-study-of-mn-166-for-chemotherapy-induced-neuropathy/
0 · Reply
JarvisFlow
JarvisFlow Dec. 18 at 1:00 PM
D. Boral Capital has updated their rating for MediciNova ( $MNOV ) to Buy with a price target of 9.
0 · Reply
DARKP00L
DARKP00L Dec. 18 at 11:13 AM
$MNOV 06:08 on Dec. 18 2025 MediciNova Completes Patient Enrollment in Mid-Stage Trial for Chemotherapy Nerve Damage #tradeideas
0 · Reply
Latest News on MNOV
2026 New Year's Greetings from the CEO

Jan 6, 2026, 9:00 AM EST - 10 days ago

2026 New Year's Greetings from the CEO

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

Dec 18, 2025, 6:00 AM EST - 4 weeks ago

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

Dec 8, 2025, 6:00 AM EST - 5 weeks ago

MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

Nov 18, 2025, 6:00 AM EST - 2 months ago

MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

Nov 6, 2025, 6:00 PM EST - 2 months ago

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

Oct 30, 2025, 7:00 PM EDT - 2 months ago

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

Oct 6, 2025, 8:00 AM EDT - 3 months ago

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

MediciNova Provides Shareholder Update on Key Developments

Sep 8, 2025, 9:00 AM EDT - 4 months ago

MediciNova Provides Shareholder Update on Key Developments

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:00 AM EDT - 4 months ago

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

Aug 26, 2025, 7:00 PM EDT - 5 months ago

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

Jul 31, 2025, 7:30 PM EDT - 6 months ago

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

Jul 24, 2025, 6:00 AM EDT - 6 months ago

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

Apr 14, 2025, 7:00 PM EDT - 9 months ago

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

Apr 8, 2025, 7:00 PM EDT - 10 months ago

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

Dec 5, 2024, 6:00 PM EST - 1 year ago

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

Nov 14, 2024, 6:00 PM EST - 1 year ago

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

Nov 11, 2024, 6:00 PM EST - 1 year ago

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

Oct 23, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

Sep 30, 2024, 9:00 AM EDT - 1 year ago

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

Sep 9, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

Sep 3, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

Aug 29, 2024, 7:00 PM EDT - 1 year ago

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

MediciNova Chief Business Officer David H. Crean, Ph.D.

Jun 20, 2024, 6:00 AM EDT - 1 year ago

MediciNova Chief Business Officer David H. Crean, Ph.D.

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

Jun 5, 2024, 6:00 AM EDT - 1 year ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Jun 3, 2024, 6:00 AM EDT - 1 year ago

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

May 28, 2024, 6:00 AM EDT - 1 year ago

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

May 20, 2024, 6:00 AM EDT - 1 year ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

May 14, 2024, 6:00 AM EDT - 1 year ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

May 7, 2024, 6:00 AM EDT - 1 year ago

MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

Apr 2, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Mar 26, 2024, 7:00 PM EDT - 1 year ago

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

Mar 20, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

Mar 12, 2024, 6:30 AM EDT - 2 years ago

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

Jan 17, 2024, 6:00 AM EST - 2 years ago

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

Dec 21, 2023, 6:00 PM EST - 2 years ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

Dec 6, 2023, 6:00 PM EST - 2 years ago

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Nov 19, 2023, 6:00 PM EST - 2 years ago

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

Oct 27, 2023, 1:00 AM EDT - 2 years ago

MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

Oct 10, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

MediciNova Receives Gene Therapy Milestone Payment

Oct 4, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives Gene Therapy Milestone Payment

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Sep 27, 2023, 7:00 PM EDT - 2 years ago

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

Aug 17, 2023, 7:00 PM EDT - 2 years ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe

Aug 16, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe

MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe

Aug 15, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe

Aug 14, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe

MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

Jun 29, 2023, 6:00 AM EDT - 2 years ago

MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe

May 14, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada

Apr 30, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada

MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Mar 9, 2023, 6:00 PM EST - 3 years ago

MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

Feb 20, 2023, 6:00 PM EST - 3 years ago

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

MuzunguZanz
MuzunguZanz Jan. 15 at 8:41 PM
$MNOV This is a 8-10 months investment but if successful you guys should be at $10
1 · Reply
thepalace2007
thepalace2007 Jan. 9 at 5:44 PM
$MNOV $5 incoming
1 · Reply
Penhouseview
Penhouseview Jan. 8 at 3:10 AM
$MNOV
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 2 at 1:37 AM
$MNOV RSI: 20.59, MACD: -0.0432 Vol: 0.11, MA20: 1.44, MA50: 1.42 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
StockElementCorporation
StockElementCorporation Dec. 30 at 1:56 PM
Premarket movers 📈 Upside: $EKSO +44% (APLD to spin out cloud business; proposes combination with Ekso to launch Chronoscale) $ONTF +36% (to be acquired by Cvent for $8.10/share, ~$400M) $SCWO +13% (awarded PFAS waste destruction project for City of St. Cloud) $MNOV +5.5% (announces up to $50M equity distribution agreement) $TE +5.0% (executes $160M sale of Section 45X tax credits) DUOT +3.2% (announces additional Texas deployment and Illinois expansion) MOH +2.7% (constructive comments from Mike Burry) APLD +2.1% (cloud business spinout, Ekso combination proposal) Downside: IFRX -4.9% (Vilobelimab Phase 3 post-hoc analyses in pyoderma gangrenosum)
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 26 at 3:52 PM
$MNOV Share Price: $1.24 Contract Selected: Jul 17, 2026 $2.5 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.07 – $0.09 Potential Upside: 59% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
LimeLightL
LimeLightL Dec. 25 at 9:37 AM
$MNOV Expectations reset as evidence replaces narrative, given the heightened sensitivity to timeline slippage. Shortfalls would likely reprice expectations quickly.
1 · Reply
prismmarketview
prismmarketview Dec. 18 at 4:11 PM
MediciNova (NASDAQ: $MNOV ) has completed enrollment in its investigator‑initiated Phase 2 OXTOX trial evaluating MN‑166 (ibudilast) to prevent chemotherapy‑induced peripheral neuropathy in metastatic colorectal cancer, with 100 patients randomized across 11 Australian sites and top‑line data expected in late 2026 after six‑month post‑chemo follow‑up. https://prismmarketview.com/medicinova-completes-enrollment-in-phase-2-study-of-mn-166-for-chemotherapy-induced-neuropathy/
0 · Reply
JarvisFlow
JarvisFlow Dec. 18 at 1:00 PM
D. Boral Capital has updated their rating for MediciNova ( $MNOV ) to Buy with a price target of 9.
0 · Reply
DARKP00L
DARKP00L Dec. 18 at 11:13 AM
$MNOV 06:08 on Dec. 18 2025 MediciNova Completes Patient Enrollment in Mid-Stage Trial for Chemotherapy Nerve Damage #tradeideas
0 · Reply
Susiita81
Susiita81 Dec. 12 at 12:20 PM
$MNOV NEW!!! Ibudilast for Parkinson's disease https://onlinelibrary.wiley.com/doi/10.1111/jnc.70321
0 · Reply
thepalace2007
thepalace2007 Dec. 11 at 3:02 PM
$MNOV keep accumulating this will fly $7 price target
1 · Reply
Jabbar19
Jabbar19 Dec. 9 at 11:10 AM
$MNOV what is behind this repeated price target news by D. Boral Capital? "MediciNova Price Target Maintained With a $9.00/Share by D. Boral Capital".
1 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 4:17 PM
D. Boral Capital updates rating for MediciNova ( $MNOV ) to Buy, target set at 9.
0 · Reply
JohnTrack
JohnTrack Dec. 2 at 7:18 PM
$MNOV to the moonnn!!
1 · Reply
doledav
doledav Dec. 2 at 12:38 PM
$MNOV it’s wild, if this technology works to reverse atherosclerosis this drug would be worth billions, high cholesterol is a huge field due to heart disease
0 · Reply
thepalace2007
thepalace2007 Dec. 2 at 3:03 AM
$MNOV press release after hours
0 · Reply
JohnTrack
JohnTrack Dec. 2 at 12:53 AM
$MNOV news tick on this name... https://www.rapidticker.com/news/mnov-message-from-the-ceo-to-cdbdc4
0 · Reply
Cocky_day_trader
Cocky_day_trader Nov. 30 at 5:48 PM
$AREB $PRPH $MNOV $ELBM $GRI big money
0 · Reply
BigTimePennyStocks
BigTimePennyStocks Nov. 30 at 5:47 PM
Small-Caps with Catalysts this week: 👇👇 ( $AREB, $PRPH, $MNOV, $ELBM, etc...) #NASDAQ #NYSE
0 · Reply
thepalace2007
thepalace2007 Nov. 25 at 6:06 PM
$MNOV super
0 · Reply
Lionish
Lionish Nov. 19 at 12:18 AM
$MNOV Solid cash position and free of long term debt. Standby Equity Purchase Agreement. Addressing unmet medical needs. Making solid progress. A biotech gem like no other. GL!
0 · Reply